Intrinsic Value of S&P & Nasdaq Contact Us

Immuron Limited IMRN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • AU • USD

SharesGrow Score
46/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Immuron Limited (IMRN) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

Analysts estimate Earnings Per Share (EPS) of $-0.03 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-1.22 vs est $-0.03 (missed -3959.6%). 2025: actual $-0.90 vs est $-0.04 (missed -2104.7%). Analyst accuracy: 3%.

IMRN Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to Immuron Limited in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — IMRN

3%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$1.22 vs Est –$0.03 ▼ 97.5% off
2025 Actual –$0.90 vs Est –$0.04 ▼ 95.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — IMRN

98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.005B vs Est $0.005B ▼ 3.6% off
2025 Actual $0.007B vs Est $0.007B ▲ 0.7% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message